{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:42:16Z","timestamp":1780987336533,"version":"3.54.1"},"reference-count":45,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Ministry of Health of the Czech Republic","award":["MH CZ\u2014DRO\u2014VFN00064165"],"award-info":[{"award-number":["MH CZ\u2014DRO\u2014VFN00064165"]}]},{"name":"Gilead Sciences s.r.o.","award":["MH CZ\u2014DRO\u2014VFN00064165"],"award-info":[{"award-number":["MH CZ\u2014DRO\u2014VFN00064165"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/Objectives: Non-fermenting Gram-negative bacilli (NFGNB) represent a significant clinical challenge due to their intrinsic and acquired resistance, particularly in immunocompromised patients. Infections cause by NFGNB are associated with high morbidity and mortality, especially among patients with cystic fibrosis and hematologic malignancies. This study aimed to assess the in vitro susceptibility of clinically relevant NFGNB isolates to two newer antibiotics, cefiderocol and aztreonam\/avibactam, and an established antibiotic, trimethoprim\/sulfamethoxazole. Methods: This retrospective, monocentric study analysed 94 NFGNB isolates (30 Pseudomonas aeruginosa, 30 Acinetobacter sp., 24 Stenotrophomonas maltophilia, and 10 Burkholderia cepacia complex). Susceptibility testing for cefiderocol, aztreonam\/avibactam, and trimethoprim\/sulfamethoxazole was conducted using gradient strip method. MIC values were interpreted using EUCAST breakpoints, ECOFFs, or alternative criteria when necessary. Results: All S. maltophilia isolates were susceptible to cefiderocol (FCR) and aztreonam\/avibactam (A\/A) based on ECOFFs, with one strain resistant to trimethoprim\u2013sulfamethoxazole (COT). Burkholderia cepacia complex strains also showed high susceptibility to FCR, with only one isolate exceeding the ECOFF for A\/A, and 20% resistant to COT. All Acinetobacter sp. isolates were susceptible to FCR; however, most MIC values clustered at or just below the ECOFF value. In P. aeruginosa, one isolate was resistant to FCR, and three isolates (10%) were resistant to A\/A. Interestingly, confirmed carbapenemase producers remained susceptible to both FCR and A\/A. Most A\/A MIC values for P. aeruginosa were just below the ECOFF. Conclusions: Cefiderocol and aztreonam\/avibactam demonstrated promising in vitro activity against clinically relevant NFGNB, including carbapenem-resistant strains. These findings support their potential role as therapeutic options for difficult-to-treat infections, particularly in immunocompromised patients.<\/jats:p>","DOI":"10.3390\/antibiotics14080762","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T12:39:29Z","timestamp":1753792769000},"page":"762","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In Vitro Activity of Cefiderocol and Aztreonam\/Avibactam Against Gram-Negative Non-Fermenting Bacteria: A New Strategy Against Highly Antibiotic-Resistant Infectious Agents"],"prefix":"10.3390","volume":"14","author":[{"given":"Jan","family":"Z\u00e1vora","sequence":"first","affiliation":[{"name":"Clinical Microbiology and ATB Centre, General University Hospital, 128 08 Prague, Czech Republic"},{"name":"Department of Medical Microbiology, Palacky University, 779 00 Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-5365","authenticated-orcid":false,"given":"V\u00e1clava","family":"Ad\u00e1mkov\u00e1","sequence":"additional","affiliation":[{"name":"Clinical Microbiology and ATB Centre, General University Hospital, 128 08 Prague, Czech Republic"},{"name":"Department of Medical Microbiology, Palacky University, 779 00 Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al\u017eb\u011bta","family":"Studen\u00e1","sequence":"additional","affiliation":[{"name":"Clinical Microbiology and ATB Centre, General University Hospital, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3607-5498","authenticated-orcid":false,"given":"Gabriela","family":"Kroneislov\u00e1","sequence":"additional","affiliation":[{"name":"Clinical Microbiology and ATB Centre, General University Hospital, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pascale, R., Corcione, S., Bussini, L., Pancaldi, L., Giacobbe, D.R., Ambretti, S., Lupia, T., Costa, C., Marchese, A., and De Rosa, F.G. (2021). Non-fermentative gram-negative bloodstream infection in northern Italy: A multicenter cohort study. BMC. Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06496-8"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2147\/IDR.S253949","article-title":"Stenotrophomonas maltophilia Infections: Clinical Characteristics and Factors Associated with Mortality of Hospitalized Patients","volume":"13","author":"Insuwanno","year":"2020","journal-title":"Infect. Drug. Resist."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/23744235.2024.2324365","article-title":"Risk factors for mortality in Stenotrophomonas maltophilia bacteremia\u2014A meta-analysis","volume":"56","author":"Huang","year":"2024","journal-title":"Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/piac052","article-title":"Opportunistic Pathogens in Cystic Fibrosis: Epidemiology and Pathogenesis of Lung Infection","volume":"11","author":"Blanchard","year":"2022","journal-title":"J. Pediatric. Infect. Dis. Soc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e14169","DOI":"10.1111\/tid.14169","article-title":"Global impact of antibacterial resistance in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"25","author":"Gottesdiener","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lupia, T., Carnevale-Schianca, F., Vita, D., Busca, A., Caravelli, D., Cris\u00e0, E., Gregorc, V., Curtoni, A., Cerutti, A., and Shbaklo, N. (2024). Stenotrophomonas maltophilia Infections in Haematological Malignancies and Hematopoietic Stem Cell Transplantation: A Case Series including Cefiderocol-Based Regimens. Medicina, 60.","DOI":"10.3390\/medicina60010088"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2025, May 21). Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0. Available online: http:\/\/www.eucast.org."},{"key":"ref_11","unstructured":"Clinical and Laboratory Standards Institute (2025, May 21). M100. Performance Standards for Antimicrobial Susceptibility Testing. 2025, 35th Edition. Available online: https:\/\/clsi.org."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/cid\/cix893","article-title":"Carbapenemase-Producing Organisms: A Global Scourge","volume":"66","author":"Bonomo","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Barrasa, H., Mor\u00e1n, M.A., Fern\u00e1ndez-Ciriza, L., Isla, A., Solin\u00eds, M.\u00c1., Canut-Blasco, A., and Rodr\u00edguez-Gasc\u00f3n, A. (2024). Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic\/Pharmacodynamic Approach. Antibiotics, 13.","DOI":"10.3390\/antibiotics13060553"},{"key":"ref_14","first-page":"1953","article-title":"Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: A review of 16 years","volume":"26","year":"2018","journal-title":"Support. Care. Cancer."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Shen, J., Ni, Y., Guan, Q., Li, R., Cao, H., Geng, Y., and You, Q. (2023). Stenotrophomonas maltophilia promotes lung adenocarcinoma progression by upregulating histone deacetylase 5. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1121863"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/mdr.2021.0353","article-title":"Susceptibility of Burkholderia cepacia complex to Ceftazidime\/Avibactam and Standard Drugs of Treatment for Cystic Fibrosis Patients","volume":"28","author":"Schaumburg","year":"2022","journal-title":"Microb. Drug. Resist."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"dlaa060","DOI":"10.1093\/jacamr\/dlaa060","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe","volume":"2","author":"Longshaw","year":"2020","journal-title":"JAC. Antimicrob. Resist."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"dlae006","DOI":"10.1093\/jacamr\/dlae006","article-title":"In vitro activity of cefiderocol and comparator antibiotics against multidrug-resistant non-fermenting Gram-negative bacilli","volume":"6","author":"Huang","year":"2024","journal-title":"JAC. Antimicrob. Resist."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.cmi.2024.11.006","article-title":"Aztreonam and avibactam combination therapy for metallo-\u03b2-lactamase-producing gram-negative bacteria: A Narrative Review","volume":"31","author":"Sangiorgio","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sader, H.S., Mendes, R.E., Ryan Arends, S.J., Doyle, T.B., and Castanheira, M. (2025). Activity of Aztreonam-avibactam and other \u03b2-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020\u20132022). BMC. Pulm. Med., 25.","DOI":"10.1186\/s12890-025-03500-8"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107803","DOI":"10.1016\/j.ijid.2025.107803","article-title":"Antimicrobial susceptibility of clinical isolates of Stenotrophomonas maltophilia from Europe, Asia, and Latin America (2018\u20132023)","volume":"153","author":"Sader","year":"2025","journal-title":"Int. J Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4103\/ijmr.IJMR_9_19","article-title":"Antimicrobial susceptibility pattern of Burkholderia cepacia complex & Stenotrophomonas maltophilia from North India: Trend over a decade (2007\u20132016)","volume":"152","author":"Sethi","year":"2020","journal-title":"Indian. J. Med. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12098-020-03346-4","article-title":"Susceptibility Patterns of Multidrug-Resistant Acinetobacter baumannii","volume":"88","author":"Konca","year":"2021","journal-title":"Indian. J. Pediatr."},{"key":"ref_24","first-page":"e75113","article-title":"Trimethoprim-Sulfamethoxazole-Induced Pancytopenia: A Case Report","volume":"16","author":"Chahal","year":"2024","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/bcp.70051","article-title":"Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta-analysis with active comparator disproportionality analysis","volume":"91","author":"Preyra","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00297-20","DOI":"10.1128\/AAC.00297-20","article-title":"Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lin, Q., Zou, H., Chen, X., Wu, M., Ma, D., Yu, H., Niu, S., and Huang, S. (2021). Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro. BMC. Microbiol., 21.","DOI":"10.1186\/s12866-021-02108-2"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/mmi.13831","article-title":"Structural\/mechanistic insights into the efficacy of nonclassical \u03b2-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates","volume":"106","author":"Hinchliffe","year":"2017","journal-title":"Mol. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/jac\/dkaa117","article-title":"Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia","volume":"75","author":"Conejo","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dky425","article-title":"In vitro activities of cefiderocol, ceftolozane\/tazobactam, ceftazidime\/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan","volume":"74","author":"Hsueh","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s10096-024-04960-2","article-title":"Cefiderocol susceptibility of 146 Stenotrophomonas maltophilia strains clinically isolated from blood in two Japanese hospitals over a 10-year period","volume":"43","author":"Sakoh","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jgar.2021.04.019","article-title":"In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy","volume":"25","author":"Stracquadanio","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"ofad500.2372","DOI":"10.1093\/ofid\/ofad500.2372","article-title":"2761. Activity of Cefiderocol and Comparator Agents Against Achromobacter and Burkholderia Isolates, Collected During 2020\u20132022 as Part of SENTRY Antimicrobial Surveillance Program","volume":"10","author":"DeJonge","year":"2023","journal-title":"Open. Forum. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e0034623","DOI":"10.1128\/aac.00346-23","article-title":"In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates","volume":"67","author":"Takemura","year":"2023","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_35","first-page":"231","article-title":"Extenzivn\u011b rezistentn\u00ed kmeny Acinetobacter baumannii nesouc\u00ed geny pro karbapenem\u00e1zu OXA-23 a metyl\u00e1zu ArmA v nemocnic\u00edch \u010cesk\u00e9 republiky [Extensively drug-resistant Acinetobacter baumannii strains carrying genes encoding carbapenemase OXA-23 and methylase ArmA in hospitals of the Czech Republic]","volume":"25","author":"Nemec","year":"2016","journal-title":"Zpr. CEM."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Xiong, L., Deng, C., Yang, G., Shen, M., Chen, B., Tian, R., Zha, H., and Wu, K. (2023). Molecular epidemiology and antimicrobial resistance patterns of carbapenem-resistant Acinetobacter baumannii isolates from patients admitted at ICUs of a teaching hospital in Zunyi, China. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1280372"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lagadinou, M., Amerali, M., Michailides, C., Chondroleou, A., Skintzi, K., Spiliopoulou, A., Kolonitsiou, F., Leonidou, L., Assimakopoulos, S.F., and Marangos, M. (2024). Antibiotic Resistance Trends in Carbapenem-Resistant Gram-Negative Pathogens and Eight-Year Surveillance of XDR Bloodstream Infections in a Western Greece Tertiary Hospital. Pathogens, 13.","DOI":"10.3390\/pathogens13121136"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jgar.2021.06.011","article-title":"In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Spain","volume":"26","author":"Cercenado","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Henriksen, A.S., Jeannot, K., Oliver, A., Perry, J.D., Pletz, M.W., Stefani, S., Morrissey, I., Longshaw, C., and ARTEMIS Study Investigators (2024). In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.03836-23"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e02531-16","DOI":"10.1128\/AAC.02531-16","article-title":"Structure and Function of the PiuA and PirA Siderophore-Drug Receptors from Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"61","author":"Luscher","year":"2017","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e00472-17","DOI":"10.1128\/AAC.00472-17","article-title":"In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Mauri, C., Maraolo, A.E., Di Bella, S., Luzzaro, F., and Principe, L. (2021). The Revival of Aztreonam in Combination with Avibactam against Metallo-\u03b2-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics, 10.","DOI":"10.3390\/antibiotics10081012"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Oliver, A., Arca-Su\u00e1rez, J., Gomis-Font, M.A., Gonz\u00e1lez-Pinto, L., and L\u00f3pez-Causap\u00e9, C. (2025). Emerging resistance mechanisms to newer \u03b2-lactams in Pseudomonas aeruginosa. Clin. Microbiol. Infect., in press.","DOI":"10.1016\/j.cmi.2025.03.013"},{"key":"ref_44","unstructured":"Liofilchem (2022). MIC Test Strip Application Guide, Liofilchem, s.r.l.. Available online: https:\/\/www.liofilchem.com\/images\/brochure\/mic_test_strip_patent\/MIC_APPLICATION_GUIDE.pdf."},{"key":"ref_45","unstructured":"(2025, May 26). The European Committee on Antimicrobial Susceptibility Testing Routine Extended Internal Quality Control for MIC determination Disk Diffusion as Recommended by EUCAST. Version 15.0. Available online: http:\/\/www.eucast.org."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/8\/762\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:17:54Z","timestamp":1760033874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/8\/762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["antibiotics14080762"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14080762","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]}}}